Omrix Biopharmaceuticals to Webcast Presentation at Credit Suisse Annual Healthcare Conference
06 Novembre 2008 - 7:47PM
Business Wire
Omrix Biopharmaceuticals, Inc. (�Omrix�) (NASDAQ: OMRI), a
fully-integrated biopharmaceutical company that develops and
markets biosurgical and immunotherapy products, announced today
that Nissim Mashiach, President & Chief Operating Officer, is
scheduled to give a company presentation at the Credit Suisse
Annual Global Healthcare Conference on Friday, November 14, 2008 at
9:00 a.m. Mountain Standard Time; 11:00 am Eastern Standard Time at
the Arizona Biltmore Resort & Spa in Phoenix, Arizona. A live
webcast of the presentation will be available on the Company's
corporate web site at www.omrix.com. Participants are urged to log
on to the web site 15 minutes prior to the scheduled start time to
download and install any necessary audio software. A replay of the
webcast will be available within 24 hours after the live
presentation time and will be available for 30 days. About Omrix
Biopharmaceuticals, Inc. Omrix is a fully integrated
biopharmaceutical company that develops, manufactures and markets
protein-based biosurgery and passive immunotherapy products. Omrix'
biosurgery product line includes products and product candidates
that are used for the control of bleeding, or hemostasis, and other
surgical applications. The Company's passive immunotherapy product
line includes antibody-rich products and product candidates for the
treatment of immune deficiencies, infectious diseases and potential
biodefense applications. For more information, please visit
www.omrix.com. Safe Harbor Statement This news release contains
forward-looking statements. Forward-looking statements provide the
Company's current expectations or forecasts of future events.
Forward-looking statements include statements about the Company's
expectations, beliefs, plans, objectives, intentions, assumptions
and other statements that are not historical facts. Forward-looking
statements are subject to known and unknown risks and uncertainties
and are based on potentially inaccurate assumptions that could
cause actual results to differ materially from those expected or
implied by the forward-looking statements. The Company's actual
results could differ materially from those anticipated in
forward-looking statements for many reasons, including the factors
described in the Company's filings with the Securities and Exchange
Commission (SEC), including sections entitled "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" in the Company's Form 10-K as filed with the
SEC on March 17, 2008, and the Company's most recent quarterly
reports on Form 10-Q and its current reports on Form 8-K. Unless
required by law, the Company undertakes no obligation to publicly
update or revise any forward-looking statement to reflect
circumstances or events after the date of this news release.
Omrix Biopharmaceuticals (MM) (NASDAQ:OMRI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Omrix Biopharmaceuticals (MM) (NASDAQ:OMRI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Omrix Biopharmaceuticals (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Omrix Biopharmaceuticals, Inc.